vs

Side-by-side financial comparison of IMMUCELL CORP (ICCC) and PURE CYCLE CORP (PCYO). Click either name above to swap in a different company.

PURE CYCLE CORP is the larger business by last-quarter revenue ($9.1M vs $5.5M, roughly 1.7× IMMUCELL CORP). PURE CYCLE CORP runs the higher net margin — 50.0% vs -2.5%, a 52.5% gap on every dollar of revenue. On growth, PURE CYCLE CORP posted the faster year-over-year revenue change (58.8% vs -8.4%). Over the past eight quarters, PURE CYCLE CORP's revenue compounded faster (69.0% CAGR vs 3.9%).

ImmuCell Corp is a US-based animal health biotechnology company that develops, manufactures and markets innovative products for livestock, primarily dairy cattle. Its core offerings include preventive and therapeutic solutions for common bovine health issues such as mastitis, serving agricultural producers and veterinary providers across North America.

Pure Cycles, is a bicycle company based in Los Angeles, California that was founded by Michael Fishman, Jordan Schau, Zachary Schau and Austin Stoffers in 2010, as Pure Fix Cycles.

ICCC vs PCYO — Head-to-Head

Bigger by revenue
PCYO
PCYO
1.7× larger
PCYO
$9.1M
$5.5M
ICCC
Growing faster (revenue YoY)
PCYO
PCYO
+67.2% gap
PCYO
58.8%
-8.4%
ICCC
Higher net margin
PCYO
PCYO
52.5% more per $
PCYO
50.0%
-2.5%
ICCC
Faster 2-yr revenue CAGR
PCYO
PCYO
Annualised
PCYO
69.0%
3.9%
ICCC

Income Statement — Q3 FY2025 vs Q1 FY2026

Metric
ICCC
ICCC
PCYO
PCYO
Revenue
$5.5M
$9.1M
Net Profit
$-139.7K
$4.6M
Gross Margin
42.9%
68.4%
Operating Margin
0.4%
48.0%
Net Margin
-2.5%
50.0%
Revenue YoY
-8.4%
58.8%
Net Profit YoY
80.1%
16.0%
EPS (diluted)
$-0.02
$0.19

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ICCC
ICCC
PCYO
PCYO
Q4 25
$9.1M
Q3 25
$5.5M
$11.2M
Q2 25
$6.4M
$5.1M
Q1 25
$8.1M
$4.0M
Q4 24
$7.8M
$5.8M
Q3 24
$6.0M
$12.6M
Q2 24
$5.5M
$7.6M
Q1 24
$7.3M
$3.2M
Net Profit
ICCC
ICCC
PCYO
PCYO
Q4 25
$4.6M
Q3 25
$-139.7K
$6.1M
Q2 25
$501.9K
$2.3M
Q1 25
$1.4M
$809.0K
Q4 24
$3.9M
Q3 24
$-701.7K
$6.6M
Q2 24
$-1.5M
$2.8M
Q1 24
$-437.9K
$118.0K
Gross Margin
ICCC
ICCC
PCYO
PCYO
Q4 25
68.4%
Q3 25
42.9%
67.7%
Q2 25
43.7%
63.4%
Q1 25
41.6%
38.2%
Q4 24
36.5%
63.8%
Q3 24
26.3%
77.8%
Q2 24
22.5%
64.0%
Q1 24
31.6%
55.6%
Operating Margin
ICCC
ICCC
PCYO
PCYO
Q4 25
48.0%
Q3 25
0.4%
53.1%
Q2 25
8.8%
26.0%
Q1 25
13.9%
-33.2%
Q4 24
8.0%
29.9%
Q3 24
-9.6%
62.0%
Q2 24
-25.3%
40.3%
Q1 24
-4.1%
-11.5%
Net Margin
ICCC
ICCC
PCYO
PCYO
Q4 25
50.0%
Q3 25
-2.5%
54.5%
Q2 25
7.8%
43.9%
Q1 25
17.9%
20.3%
Q4 24
68.4%
Q3 24
-11.7%
52.6%
Q2 24
-28.0%
37.2%
Q1 24
-6.0%
3.7%
EPS (diluted)
ICCC
ICCC
PCYO
PCYO
Q4 25
$0.19
Q3 25
$-0.02
$0.26
Q2 25
$0.06
$0.09
Q1 25
$0.16
$0.03
Q4 24
$0.09
$0.16
Q3 24
$-0.09
$0.27
Q2 24
$-0.20
$0.12
Q1 24
$-0.06
$0.00

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ICCC
ICCC
PCYO
PCYO
Cash + ST InvestmentsLiquidity on hand
$3.9M
$17.1M
Total DebtLower is stronger
$9.5M
$8.0M
Stockholders' EquityBook value
$29.8M
$147.5M
Total Assets
$45.7M
$168.1M
Debt / EquityLower = less leverage
0.32×
0.05×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ICCC
ICCC
PCYO
PCYO
Q4 25
$17.1M
Q3 25
$3.9M
$21.9M
Q2 25
$14.4M
Q1 25
$16.5M
Q4 24
$3.8M
$19.0M
Q3 24
$22.1M
Q2 24
$1.3M
$20.5M
Q1 24
$960.3K
$20.6M
Total Debt
ICCC
ICCC
PCYO
PCYO
Q4 25
$8.0M
Q3 25
$9.5M
$6.8M
Q2 25
$6.9M
Q1 25
$8.7M
$6.9M
Q4 24
$9.0M
$6.9M
Q3 24
$9.4M
$6.9M
Q2 24
$9.8M
Q1 24
$10.2M
Stockholders' Equity
ICCC
ICCC
PCYO
PCYO
Q4 25
$147.5M
Q3 25
$29.8M
$142.7M
Q2 25
$29.9M
$136.7M
Q1 25
$29.0M
$134.4M
Q4 24
$27.5M
$133.6M
Q3 24
$26.4M
$129.7M
Q2 24
$23.5M
$123.2M
Q1 24
$24.6M
$120.4M
Total Assets
ICCC
ICCC
PCYO
PCYO
Q4 25
$168.1M
Q3 25
$45.7M
$162.3M
Q2 25
$46.7M
$151.7M
Q1 25
$45.6M
$149.7M
Q4 24
$45.1M
$149.7M
Q3 24
$44.4M
$147.4M
Q2 24
$41.9M
$140.4M
Q1 24
$43.1M
$135.2M
Debt / Equity
ICCC
ICCC
PCYO
PCYO
Q4 25
0.05×
Q3 25
0.32×
0.05×
Q2 25
0.05×
Q1 25
0.30×
0.05×
Q4 24
0.33×
0.05×
Q3 24
0.36×
0.05×
Q2 24
0.42×
Q1 24
0.41×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ICCC
ICCC
PCYO
PCYO
Operating Cash FlowLast quarter
$-1.2M
$-979.0K
Free Cash FlowOCF − Capex
$-1.8M
FCF MarginFCF / Revenue
-32.3%
Capex IntensityCapex / Revenue
10.8%
Cash ConversionOCF / Net Profit
-0.21×
TTM Free Cash FlowTrailing 4 quarters
$715.4K

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ICCC
ICCC
PCYO
PCYO
Q4 25
$-979.0K
Q3 25
$-1.2M
$9.4M
Q2 25
$1.6M
$-503.0K
Q1 25
$1.6M
$-1.4M
Q4 24
$-3.1K
$5.7M
Q3 24
$-639.3K
$3.1M
Q2 24
$581.8K
$892.0K
Q1 24
$418.5K
$-457.0K
Free Cash Flow
ICCC
ICCC
PCYO
PCYO
Q4 25
Q3 25
$-1.8M
Q2 25
$1.4M
Q1 25
$1.2M
Q4 24
$-199.3K
Q3 24
$-727.7K
Q2 24
$471.0K
Q1 24
$348.1K
FCF Margin
ICCC
ICCC
PCYO
PCYO
Q4 25
Q3 25
-32.3%
Q2 25
22.4%
Q1 25
15.4%
Q4 24
-2.6%
Q3 24
-12.1%
Q2 24
8.6%
Q1 24
4.8%
Capex Intensity
ICCC
ICCC
PCYO
PCYO
Q4 25
Q3 25
10.8%
Q2 25
2.4%
Q1 25
4.1%
Q4 24
2.5%
Q3 24
1.5%
Q2 24
2.0%
Q1 24
1.0%
Cash Conversion
ICCC
ICCC
PCYO
PCYO
Q4 25
-0.21×
Q3 25
1.53×
Q2 25
3.19×
-0.22×
Q1 25
1.09×
-1.70×
Q4 24
1.44×
Q3 24
0.47×
Q2 24
0.32×
Q1 24
-3.87×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ICCC
ICCC

Segment breakdown not available.

PCYO
PCYO

Construction$6.5M71%
Water And Wastewater Resource Development Segment$2.5M27%

Related Comparisons